The National Health Surveillance Agency (Anvisa) and Dinavisa have formalized a technical cooperation aimed at expanding inspection and safety actions for medicines and products in Brazil. The agreement represents a significant advance in the country's health surveillance strategies.
The partnership between the two institutions seeks to intensify the monitoring of medicines and pharmaceutical products circulating in the domestic market, reinforcing quality control mechanisms and regulatory compliance. This collaboration enables resource optimization and information sharing between the agencies, enhancing their capacity to respond to potential health risks.
With the implementation of this cooperation, it is expected to raise the safety standards of products made available to the Brazilian population. The measure aligns with Anvisa's commitments to ensure that medicines and pharmaceutical products maintain compliance with applicable technical standards and regulations.
Anvisa, a federal agency responsible for health surveillance, has the responsibility to guarantee the efficacy, safety, and quality of medicines, cosmetics, food, and other products under its jurisdiction. Dinavisa complements these actions with additional expertise in inspection and health surveillance.
This cooperation demonstrates the institutions' commitment to maintaining a robust and reliable regulatory environment, essential for protecting public health and ensuring that only appropriate products reach Brazilian consumers. Strengthening inspection efforts contributes to increasing confidence in the national health surveillance system and reaffirms the fundamental role of these agencies in protecting the health of the population.
